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Abstract Small, benign, or low-grade malignant tumors located in the neck of the pancreas are usually treated with
enucleation. However, if enucleation is too risky because of possible damage of the main pancreatic duct, standard
pancreatic resections are performed. Such operations can lead to impaired long-term exocrine–endocrine function. Middle
segment pancreatectomy consists of a limited resection of the midportion of the pancreas and can be performed in selected
patients affected by tumors of the pancreatic neck. Middle segment pancreatectomy is a safe and feasible procedure for
treating tumors of the pancreatic neck; in experienced hands it is associated with no mortality but with high morbidity, even
if the rate of “clinical” pancreatic fistula is about 20%. Moreover, it allows a surgeon to preserve pancreatic parenchyma and
consequently long-term endocrine and exocrine pancreatic function.
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Introduction
Whereas neoplastic lesion located in the pancreatic head or
body-tail are usually resected by pancreaticoduodenectomy
or distal pancreatectomy, tumors in the neck represent a real
challenge for a surgeon. In these cases, standard or
extended pancreatectomies performed for benign or bor-
derline cases can determine the loss of a great amount of
glandular tissue, significantly increasing the risk of diabe-
tes, impaired exocrine function, and splenic loss.
1–6
Enucleation would be an adequate alternative for small,
benign, and low-grade malignant tumors, such as endocrine
and cystic neoplasms of the pancreas. Unfortunately this
conservative procedure cannot be always applicable. When
the neoplastic lesion measures up to 2 cm or more, or it is
encased within the pancreatic gland, enucleation is associ-
ated with a high risk of Wirsung’s duct damage; moreover
in the case of tumors with uncertain biological behavior this
approach should be avoided because of the risk of tumor
recurrence
1–5.
Letton and Wilson
7 reported for the first time in the
English literature in 1959 two cases of traumatic mid-
pancreatic transection followed by a reconstruction with a
Roux-en-Y jejunal loop anastomized to the distal part of the
gland. Dagradi and Serio,
8 from our own Department of
Surgery, were the first in 1984 to propose middle
pancreatectomy with an “oncological” indication, treating
a pancreatic insulinoma. Subsequently, other authors
reported cases of resection of the middle pancreas, of
varying extent, using various terms such as “central
pancreatectomy,”“ middle segment pancreatectomy,”“ seg-
mental pancreatectomy,” and “intermediate pancreatecto-
my.”
9–13 The underlying indications for surgery ranged from
chronic pancreatitis to benign, uncertain behavior, or low-
grade malignant exocrine and endocrine neoplasms
1–19.
Different techniques were adopted for gastrointestinal
reconstruction, including jejunal anastomosis of both the
proximal and distal stump, or of only the distal stump, with
pancreaticoduodenal or pancreaticogastric anastomosis.
1–21
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The abdomen is entered through a midline incision. The
gastrocolic ligament is opened, preserving the gastroepiploic
vessels, and the pancreatic gland is exposed. The posterior
peritoneum along the superior and inferior margin of the
pancreas is incised. The superior mesenteric vein and the
portal vein must be identified and their surfaces cleared
below the gland. The plane between the superior mesenteric
and portal vein should be teased apart. The splenic artery and
vein are dissected free and separated from the gland. Some
venous tributaries to the portomesenteric axis and some
minor collaterals of the splenic artery can be ligated. Then,
the posterior surface of the pancreatic neck is isolated from
the portomesenteric axis and a ribbon is passed behind the
gland to elevate it. Sutures are placed along the superior and
inferior margins to indicate where the proximal and distal
transection should be performed and to ligate those vessels
runningalong the margins. The segment of the pancreas with
the tumor is subsequently transected through a knife or a
stapler to the left and to the right of the lesion. The cephalic
stump is sutured with interrupted stitches after elective
ligation of the Wirsung’s duct or by means of a stapler. A
small stent is placed in the main pancreatic duct while
performing pancreojejunostomy or pancreogastrostomy; the
stent can be left in place, even if in our experience we have
never done it. Two closed-system suction drains are used to
drain the cephalic stump of the gland and the pancreatico-
jejunostomy/pancreaticogastrostomy.
Discussion
It has been shown that standard pancreatic resections are
nowadays associated with low mortality and morbidity if
performed in high-volume centers by experienced sur-
geons.
22–24 It is remarkable that this type of surgery can
lead to long-term complications, such as diabetes, exocrine
insufficiency, and late postsplenectomy infection
25,26.
The incidence of postoperative exocrine and endocrine
impairment is not predictable in patients with apparently
“normal pancreas.” Factors such as fibrosis of the remnant,
Wirsung’s duct obstruction, preexisting chronic pancreati-
tis, benign or malignant disease, and subclinical diabetes
may play a role as “risk factors.”
1–3 After standard left-
sided resection there is an increased incidence of endocrine
impairment and onset of diabetes reported from 17 to 85%
of patients; it is reasonable that the extent of the resection is
strictly related to the incidence of endocrine–exocrine long-
term insufficiency
27–31.
For all these reasons, more conservative surgical
techniques have been advocated for small, benign, or low-
grade malignant tumors located in the neck of the gland,
aimed for sparing, as much as possible, pancreatic
parenchyma. Whenever neoplastic lesions are not small
and superficial enough to be simply enucleated, middle
segment pancreatectomy should be considerated.
1–6
Middle segment pancreatectomy accounts for only 3% of
the pancreatic resections performed at our institution and
about 100 cases have been reported in the English
literature
1–21,32–34: this means careful selection of patients.
In fact, the small number of patients who underwent this
type of operation is related to different factors: specific
localizations of the neoplasm, well-selected indications
(benign or low-grade malignant tumors), and a distal
pancreatic stump of at least 5 cm in length.
Some authors
1,3 have reported that this operation can be
performed only in the case of small tumors (<5 cm in
diameter); in our experience, although the mean diameter of
the resected lesions was 27.4 mm, we have safely per-
formed middle segment resection for tumor measuring
more than 5 cm, harboring from the anterior face of the
pancreas.
Middle segment pancreatectomy was also occasionally
used for malignant disease: two islet cell carcinomas, one
vipoma who subsequently developed hepatic metastases,
one cystadenocarcinoma, and one carcinoma in situ
2,3,10–12.
In the past we have also performed this operation for
malignant tumor but we had pancreatic recurrence of the
tumor in two patients (one affected by metastasis and one
by intraductal papillary mucinous neoplasms [IPMN] with
in situ carcinoma); moreover, two patients with adenoma
and borderline main duct IPMN had a tumor recurrence in
the pancreatic gland. Thus, we believe that in patients
affected by primary or metastatic malignant tumor, a
standard resection would be more appropriate. Moreover,
middle pancreatectomy in our experience should also be
avoided in patients affected by IPMN, especially main duct
type because of their potential malignity and the possibility
to have different degrees of dysplasia along the Wirsung’s
duct in the same patients.
The surgeon must be sure to achieve tumor-free
proximal and distal resection margins after performing
middle segment pancreatectomy and, for this reason, frozen
section examination is mandatory.
Middle segment pancreatectomy is a meticulous proce-
dure. There is the possibility of leaks from both the closed
cut edge of the head and the pancreaticojejunostomy,
considering that in most patients we are dealing with a
normal soft pancreatic texture with a small Wirsung’s duct.
Thus, not only great care must be taken in selecting the
patients who will benefit from this operation, but also an
experienced pancreatic surgeon working in a high-volume
center is required for performing the procedure.
1–4,6,32,33
Median pancreatectomy is reported to be associated with
no mortality but with a high postoperative morbidity, above
422 J Gastrointest Surg (2007) 11:421–424all consisting of pancreatic fistula.
6 In our experience the
“clinical” pancreatic fistula rates after pancreaticoduodenec-
tomy and left pancreatectomy are 10 and 20%, respective-
ly.
23,35–37 Between January 1990 and December 2005 61
patients underwent middle segment pancreatectomy at our
institution. The incidence of pancreatic fistula—according to
the International Study Group on Pancreatic Fistula defini-
tion
22—was 51%. It is remarkable that most patients
complained of Grade A fistula, which is a “biochemical”
fistulawithoutanyclinicalimpact,whereas13patients(21%)
developed a grade B or C fistula, which required prolonged
in-hospital stay. In almost all patients the conservative
management was successful; no one underwent reoperation
andinfourcasesintraabdominalcollectionsweretreatedwith
ultrasound-guided drainage. The mortality rate was zero.
The risk of developing a pancreatic fistula must be taken
into account in the preoperative decision making; we
believe that this risk is acceptable when the procedure is
performed in a high-volume center and for patients with a
long-life expectancy, such as young or middle-aged people
affected by benign or low-grade tumors.
The most important advantage of middle segment
pancreatectomy is the good endocrine and exocrine long-
term function.
1–6,10 Iacono et al.
1 in a series of 13 patients
demonstrated that postoperative oral glucose tolerance,
pancreaticolauryl and fecal fat excretion were normal in all
cases and they studied six patients pre- and postoperatively
with oral glucose tolerance test showing no significant
differences before and after surgery. Moreover, Sperti et
al.
3 showed, in a review of the literature, no case of impaired
endocrinefunctionin59evaluablepatientswhereasexocrine
function was reported to be normal in 56 out of 59.
Another advantage of this procedure is the possibility to
preserve the spleen, preventing the risk of postsplenectomy
sepsis and hematologic disorders, which is low but exists in
an adult.
38,39
In conclusion, middle segment pancreatectomy is a safe
and technically feasible surgical approach for removing
pancreatic neck tumors in well-selected patients; in experi-
enced hands it is associated with no mortality but with high
morbidity. Most of the complications do no require reoper-
ation or prolonged in-hospital stay and can be successfully
managed conservatively. Moreover, it allows the surgeon to
preserve pancreatic parenchyma and consequently long-term
endocrine and exocrine pancreatic function.
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